2020-2021 Columbia Life Science Accelerators Announce Pilot Grant Awardees

July 01, 2021

Twelve winning research teams led by Columbia University faculty, across diverse disciplines, have received a Columbia Life Science Accelerator pilot grant for their creative and inventive lab-to-market projects. Award recipients, representing areas of expertise from bioengineering to mechanical engineering and genetics to systems biology, are each focusing on research or inventions that are on a path to commercialization or the clinic via novel therapeutics discovery or technologies that aim to change the way patients are being treated or diagnosed.

The recipients were selected for their potential to translate their research from the lab to commercial market, the scientific novelty and clinical merit of the project, and the feasibility of the proposed work. The teams this year share a total of $780,500 in pilot funding. 

The annual Life Science Accelerator pilots are co-funded by  the Irving Institute for Clinical and Translational Research through its Translational Therapeutics Accelerator (TRx); the Herbert Irving Comprehensive Cancer Center through its Accelerating Cancer Therapeutics (ACT) program; and Columbia Engineering through its Biomedical Engineering Technology Accelerator, or BiomedX(link is external and opens in a new window). The three groups work closely with Columbia Technology Ventures (CTV), a central hub at the University for technology development initiatives, entrepreneurial activities, and external industry collaborations, and by the Columbia Lab-to-Market Accelerator Network, a framework to successfully develop, launch, and execute initiatives to help commercialize academic research.

Learn more about the awardees HERE!